AQP9 and metabolic dysfunction-associated steatotic liver disease: Nevertheless, the pharmacological interest toward liver AQP9 is strong as this aquaglyceroporin has good potentials to be a novel molecular target for therapeutic intervention in NAFLD and NASH.